Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Ustekinumab: Effects on quality of life and sexual difficulties associated with psoriasis

Results from two randomized, placebo-controlled, crossover trials in 1,996 patients with moderate-severe psoriasis treated with ustekinumab were analyzed regarding aspects of quality of life (QoL) and sexual difficulties. QoL was assessed using the Dermatology Life Quality Index (DLQI) and psoriasis severity by the Psoriasis Area and Severity Index (PASI). At baseline the mean DLQI was 12, but at week 12 significant changes were seen in the ustekinumab group (-9.13) versus the placebo group (-0.53; P < 0.001). Impaired sexual function was reported by 22.6% of patients at baseline and at week 12. This had decreased to 2.7% in the ustekinumab patients; there was no change in the placebo group (P < 0.001). Improvements ...